/INVVY
INVVY Stock - Indivior PLC
Healthcare|Drug Manufacturers - Specialty & GenericOTC
$21.85+0.00%
+$0.00 (+0.00%) • Jun 9
64
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.38
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $24.03
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for INVVY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$21.63 – $22.06
TARGET (TP)$25.12
STOP LOSS$20.10
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.06
52W High$75.65
52W Low$14.76
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.19B | $1.09B | $901.00M | $791.00M | $647.00M |
| Gross Profit | $957.00M | $919.00M | $750.00M | $664.00M | $550.00M |
| Gross Margin | 80.6% | 84.1% | 83.2% | 83.9% | 85.0% |
| Operating Income | $32.00M | $-156,000,000 | $-81,000,000 | $213.00M | $-156,000,000 |
| Net Income | $2.00M | $-129,000,000 | $-44,000,000 | $205.00M | $-148,000,000 |
| Net Margin | 0.2% | -11.8% | -4.9% | 25.9% | -22.9% |
| EPS | $0.02 | $0.01 | $-0.37 | $1.38 | $-1.08 |
Company Overview
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
0%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
0 Bullish0 Neutral/Bearish
Price Targets
No price targets available
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 24th 2022 | Morgan Stanley | Upgrade | Overweight | - |
Earnings History & Surprises
INVVYBeat Rate
0%
Last 1 quarters
Avg Surprise
-30.0%
EPS vs Estimate
Beats / Misses
0/1
Last 12 quarters
Latest EPS
$0.28
Q2 2023
EPS Surprise History
Q3 21
No data
Q4 21
No data
Q2 22
No data
Q3 22
No data
Q3 22
No data
Q4 22
No data
Q1 23
No data
Q2 23
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2023 | Jun 15, 2023 | — | $0.28 | — | — |
Q1 2023 | Mar 31, 2023 | — | $0.31 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-1.27 | — | — |
Q3 2022 | Sep 30, 2022 | — | $1.45 | — | — |
Q3 2022 | Jul 28, 2022 | — | $0.30 | — | — |
Q2 2022 | Apr 28, 2022 | — | $0.30 | — | — |
Q4 2021 | Oct 27, 2021 | — | $0.15 | — | — |
Q3 2021 | Jul 29, 2021 | — | $0.30 | — | — |
Q2 2021 | Apr 29, 2021 | — | $0.25 | — | — |
Q4 2020 | Oct 28, 2020 | — | $0.12 | — | — |
Q3 2020 | Jul 29, 2020 | — | $0.11 | — | — |
Q1 2020 | Feb 13, 2020 | — | $-0.25 | — | — |
Q4 2019 | Oct 31, 2019 | — | $0.30 | — | — |
Q3 2019 | Jul 31, 2019 | — | $0.50 | — | — |
Q2 2019 | May 2, 2019 | — | $0.60 | — | — |
Q1 2019 | Feb 14, 2019 | — | $0.45 | — | — |
Q4 2018 | Nov 1, 2018 | — | $0.40 | — | — |
Q3 2018 | Jul 26, 2018 | — | $0.45 | — | — |
Q1 2018 | Feb 15, 2018 | $0.50 | $0.35 | -30.0% | ✗ MISS |
Q4 2017 | Nov 2, 2017 | — | $0.30 | — | — |
Latest News
Loading news...
Frequently Asked Questions about INVVY
What is INVVY's current stock price?
Indivior PLC (INVVY) is currently trading at $21.85 per share. The stock has moved +0.00% today.
What is the analyst price target for INVVY?
No analyst price targets are currently available for this stock.
What sector is Indivior PLC in?
Indivior PLC operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the OTC exchange.
What is INVVY's market cap?
Indivior PLC has a market capitalization of $3.01 billion, making it a mid-cap company.
Does INVVY pay dividends?
No, Indivior PLC does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARHCF
Alfresa Holdings Corporation
$11.87
Mkt Cap: $2.2B
ASPHF
Ascentage Pharma Group International
$8.48
Mkt Cap: $3.2B
DUTV
Digital Utilities Ventures, Inc.
$0.55
Mkt Cap: $1.9B
GALNF
Galenica AG
$116.19
Mkt Cap: $5.8B
KARBF
Karo Pharma AB (publ)
$5.25
Mkt Cap: $1.5B
MITPF
Mithra Pharmaceuticals S.A.
$23.90
Mkt Cap: $1.6B
MPSYF
MorphoSys AG
$73.27
Mkt Cap: $2.8B
NHNKF
Nihon Kohden Corporation
$15.07
Mkt Cap: $2.5B
SGIPF
Sugi Holdings Co.,Ltd.
$16.29
Mkt Cap: $2.9B
TKBIF
Takara Bio Inc.
$23.20
Mkt Cap: $2.8B
Explore stocks similar to INVVY for comparison